Phathom Pharmaceuticals to Report Third Quarter 2025 Financial Results and Provide Business Update on Thursday, October 30, 2025
Phathom Pharmaceuticals (Nasdaq: PHAT) announced it will report third quarter 2025 financial results and provide a business update via live webcast on Thursday, October 30, 2025 at 8:00 AM EDT.
Rhea-AI Summary
Phathom Pharmaceuticals (Nasdaq: PHAT) announced it will report third quarter 2025 financial results and provide a business update via live webcast on Thursday, October 30, 2025 at 8:00 AM EDT.
The live webcast and presentation materials will be available on the company's Events & Presentations page and a recording will be posted for 90 days after the call. Phathom develops gastrointestinal therapies and markets VOQUEZNA (vonoprazan) products in the U.S., including VOQUEZNA tablets for GERD and VOQUEZNA DUAL PAK/TRIPLE PAK for H. pylori treatment.
Media and investor contact details are provided for additional inquiries.
Positive
- None.
Negative
- None.
Details
News Market Reaction – PHAT
On Oct 20, the day this news came out, PHAT closed 8.10% above the previous close.
Data tracked by StockTitan Argus for the Oct 20 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Management to host conference call on Thursday, October 30, 2025, at 8:00 am EDT
FLORHAM PARK, N.J., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that it will host a live webcast at 8:00 am EDT on Thursday, October 30, 2025, to report its third quarter 2025 financial results and provide a business update.
A live webcast and additional information about the presentation can be accessed on the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the call.
About Phathom Pharmaceuticals, Inc.
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases. Phathom has in-licensed the exclusive rights to vonoprazan, a first-in-class potassium-competitive acid blocker (PCAB), for the U.S., Europe and Canada. Phathom currently markets vonoprazan in the United States as VOQUEZNA® (vonoprazan) tablets for the relief of heartburn associated with Non-Erosive GERD in adults, the healing and maintenance of healing of Erosive GERD in adults and relief of associated heartburn, and as part of the VOQUEZNA® TRIPLE PAK® (vonoprazan tablets, amoxicillin capsules, clarithromycin tablets) and VOQUEZNA® DUAL PAK® (vonoprazan tablets, amoxicillin capsules) for the treatment of H. pylori infection in adults. For more information about Phathom, visit the company’s website at www.phathompharma.com and follow on LinkedIn and X.
MEDIA CONTACT
Nick Benedetto
1-877-742-8466
media@phathompharma.com
INVESTOR CONTACT
Eric Sciorilli
1-877-742-8466
ir@phathompharma.com
© 2025 Phathom Pharmaceuticals. All rights reserved. VOQUEZNA, VOQUEZNA DUAL PAK, VOQUEZNA TRIPLE PAK, Phathom Pharmaceuticals, and their respective logos are registered trademarks of Phathom Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.